HOME >> BIOLOGY >> NEWS
FDA approves AVELOX (moxifloxacin HCl) for treatment of complicated intra-abdominal infections

as effective as the widely used I.V. therapy piperacillin-tazobactam four times daily followed by oral amoxicillin-clavulanate twice daily. AVELOX was effective at eradicating key pathogens, including E. coli and the anaerobe B. fragilis, which are the most commonly encountered bacteria in cIAI.

"This FDA approval signals yet another important milestone for AVELOX, following the approval of AVELOX for treatment of complicated skin and skin structure infections in June," said Robert J. Spiegel, M.D., chief medical officer and senior vice president of medical affairs, Schering-Plough Research Institute. "By adding two new indications this year, AVELOX has successfully expanded its utility as a broad-spectrum antibiotic. This will help toward AVELOX becoming a fluoroquinolone of choice for its approved indications."

Patients taking AVELOX for cIAI treatment benefit from the convenience of once-daily therapy and not requiring dosage adjustments when switching from I.V. to oral therapy. Dosage adjustments also are not required for AVELOX patients suffering from renal impairment.

In October 2004, Schering-Plough acquired exclusive U.S. rights to market, sell and distribute AVELOX from Bayer Pharmaceuticals Corporation. As holder of the New Drug Application (NDA) and patents for AVELOX, Bayer completed the research and FDA submission related to this new indication.

The FDA approval to treat cIAI is the sixth indication for AVELOX, which is already approved in the United States to treat acute bacterial sinusitis (ABS); acute bacterial exacerbation of chronic bronchitis (ABECB); community acquired pneumonia (CAP) including CAP caused by multi-drug resistant Streptococcus pneumoniae (MRSP) and penicillin-resistant Streptococcus pneumoniae (PRSP); uncomplicated skin and skin structure infections (uSSSI); and complicated skin and skin structure infections (cSSSI).


'"/>


30-Nov-2005


Page: 1 2

Related biology news :

1. FDA approves new epilepsy indication for Lamictal
2. US govt approves multi-million $ wild bird avian flu surveillance network
3. FDA approves extended dosing of Aranesp
4. FDA approves first medical device using Rutgers biomaterial
5. DFG approves additional six research training groups
6. FDA approves ABRAXANE(TM) for metastatic breast cancer
7. AVELOX as effective as multi-dose combination therapy for intra-abdominal infections
8. New system of wastewater treatment could reduce the size of treatment plants by half
9. UCF research links proteins, stem cells and potential Alzheimers treatment
10. Geisinger scientist seeks cure for Lou Gehrigs disease, creating device to find treatment
11. System to analyze beating heart stem cells could lead to heart attack treatments

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/20/2017)... DAL ) customers now can use fingerprints instead of their boarding ... ... biometrics to board aircraft at Reagan Washington National Airport ... Delta,s biometric boarding pass experience that launched in May at the ... to allow eligible Delta SkyMiles Members who are enrolled in CLEAR to ...
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at VivaTech ... startups and global businesses, taking place in Paris ... will showcase the solutions they have built with IBM Watson ... France is one of the most dynamic ... in the number of startups created between 2012 and 2015*, ...
(Date:5/16/2017)... , May 16, 2017   Bridge Patient ... organizations, and MD EMR Systems , an ... partner for GE, have established a partnership to ... product and the GE Centricity™ products, including Centricity ... These new integrations will allow ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... 11, 2017 , ... Proscia Inc ., a data ... titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, ... and how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... implantation and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... and maternal age to IVF success. , After comparing the results from the ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the ... for Excellence in Volunteer Experience from US2020. , US2020’s mission is to change ...
(Date:10/10/2017)... ... 10, 2017 , ... USDM Life Sciences , the ... sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer Jaye ... GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to achieving ...
Breaking Biology Technology:
Cached News: